Mendus AB (publ) Total Liabilities
Mendus AB (publ) total liabilities. Based on the latest financial reports, Mendus AB (publ) (IMMU) has total liabilities worth Skr69.03 Million SEK (≈ $7.43 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check asset resilience ratio of Mendus AB (publ) to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Mendus AB (publ) (2009–2025)
Total liabilities of Mendus AB (publ) from 2009 to 2025. This chart illustrates how Mendus AB (publ)'s total liabilities have evolved over time, based on quarterly financial data. Explore Mendus AB (publ) (IMMU) investment intensity to see how much of total assets are deployed in long-term investments.
Mendus AB (publ) Competitors by Total Liabilities
The table below lists competitors of Mendus AB (publ) ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
GSE Co. Ltd
KQ:053050
|
Korea | ₩113.08 Billion |
|
Drax Group PLC
LSE:DRX
|
UK | GBX3.02 Billion |
|
Hyunwoo Industrial Co. LTD
KQ:092300
|
Korea | ₩94.81 Billion |
|
KWANGJIN WINTEC CO. Ltd
KQ:090150
|
Korea | ₩45.50 Billion |
|
ContextVision AB
OL:CONTX
|
Norway | Nkr35.12 Million |
|
T&R Biofab Co. Ltd
KQ:246710
|
Korea | ₩72.55 Billion |
|
DPS Resources Bhd
KLSE:7198
|
Malaysia | RM90.39 Million |
|
Kleannara
KO:004540
|
Korea | ₩455.71 Billion |
Liability Composition Analysis (2009–2025)
This chart breaks down Mendus AB (publ)'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see total assets of Mendus AB (publ).
Liquidity & Leverage Metrics
Mendus AB (publ) Total Liabilities Ratios Explained
Mendus AB (publ) total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.53 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.12 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.11 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Mendus AB (publ)'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Mendus AB (publ) (2009–2025)
The table below shows the annual total liabilities of Mendus AB (publ) from 2009 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | Skr43.26 Million ≈ $4.66 Million |
-15.54% |
| 2024-12-31 | Skr51.22 Million ≈ $5.51 Million |
-0.02% |
| 2023-12-31 | Skr51.23 Million ≈ $5.51 Million |
-51.65% |
| 2022-12-31 | Skr105.95 Million ≈ $11.40 Million |
+64.92% |
| 2021-12-31 | Skr64.24 Million ≈ $6.91 Million |
-4.92% |
| 2020-12-31 | Skr67.57 Million ≈ $7.27 Million |
+117.62% |
| 2019-12-31 | Skr31.05 Million ≈ $3.34 Million |
-29.96% |
| 2018-12-31 | Skr44.33 Million ≈ $4.77 Million |
-21.66% |
| 2017-12-31 | Skr56.59 Million ≈ $6.09 Million |
+194.98% |
| 2016-12-31 | Skr19.18 Million ≈ $2.06 Million |
+27.39% |
| 2015-12-31 | Skr15.06 Million ≈ $1.62 Million |
+135.04% |
| 2014-12-31 | Skr6.41 Million ≈ $689.52K |
-31.06% |
| 2013-12-31 | Skr9.29 Million ≈ $1.00 Million |
+344.35% |
| 2012-12-31 | Skr2.09 Million ≈ $225.08K |
+26.97% |
| 2011-12-31 | Skr1.65 Million ≈ $177.28K |
-29.20% |
| 2010-12-31 | Skr2.33 Million ≈ $250.40K |
+113.00% |
| 2009-12-31 | Skr1.09 Million ≈ $117.56K |
-- |
About Mendus AB (publ)
Mendus AB (publ), a biopharmaceutical company, develops immunotherapies for the treatment of tumor recurrence and established tumors. Its lead product is vididencel (DCP-001), which is in Phase II ADVANCE-II clinical trial for the treatment of acute myeloid leukemia (AML); Phase II CADENCE clinical trial to treat AML; and Phase I ALISON clinical trial for the treatment of ovarian cancers. The com… Read more